NuScale Stock Is Down 83% -- Bargain or Trap? The Honest Answer Will Surprise You.

NuScale Power shares have collapsed about 83% from the $57 52-week high to sub-$10, with the article citing extremely weak fundamentals: roughly $75,000 in last-quarter revenue, no firm first sale, and ongoing cash burn. The stock faces dilution risk from a $750 million share sale and uncertainty after the loss of long-term shareholder Fluor, plus a $506 million milestone payment to ENTRA1 Energy tied to a potential TVA SMR deployment. Net-net: the update reinforces a high-risk, high-reward setup with significant execution and financing uncertainty for SMR commercialization.

Analysis

SMR is no longer being priced as a clean thematic call on nuclear adoption; it is being priced as a pre-commercial capital structure with a technology warrant attached. Over the next 1-3 months, the dominant variable is not engineering progress but financing optionality: every delay in signed backlog raises the probability that future equity comes at a punitive discount, which compresses the multiple regardless of sector enthusiasm.

The second-order winner is the rest of the nuclear value chain with actual revenue visibility: established suppliers and operators like BWXT, CCJ, and utility-scale baseload names should absorb some of the capital that would otherwise chase speculative SMR developers. FLR’s reduced exposure matters less for its own earnings than for signaling; sponsor exits tend to widen the spread investors demand from adjacent early-stage infrastructure names, making the next financing round harder not just for SMR but for the broader SMR cohort.

Contrarianly, the market may be underestimating how much policy support can matter if a real utility contract lands, but it is overestimating how quickly that can translate into economics. One signed deployment can trigger a squeeze, yet absent a non-dilutive funding source or firm first sale, the stock remains vulnerable to a path where commercial proof slips 6-18 months and the equity is valued as a cash runway story. The clean falsifier is a credible contract plus financing package; the downside case is another quarter of burn with no conversion to backlog.

Key Decisions for Investors

• Short SMR on any relief rally or buy 3-6 month put spreads; risk/reward favors downside if no firm sale or financing is announced, with a tactical stop above the pre-rally breakout level.
• Prefer a basket expression of nuclear exposure over single-name SMR: long NLR or BWXT versus short SMR for a 1-3 month relative-value trade that isolates commercialization risk from sector beta.
• No fresh long in FLR on this headline; the shareholder exit is a sentiment overhang for the SMR complex, but not a reason to change FLR earnings estimates. Treat any weakness in FLR as separate from the SMR story unless project backlog is also revised.
• Watch for a signed utility deployment or non-dilutive financing as the only credible reversal catalyst; if absent by the next earnings cycle, maintain a bearish bias and expect another capital raise to pressure the equity.